Medi-Span Releases Controlled Substances File to Help U.S. Customers Meet Compliance Requirements at Federal, State, and Territory Level
<0> Wolters Kluwer Health|Clinical SolutionsMargi Herwald Zitelli, Marketing Communications Specialist, 330-650-6506 </0>
Along with federal regulations of controlled substances through the Drug Enforcement Agency, individual states and U.S. territories may also have their own regulations that may differ from each other and those at the federal level. The Controlled Substances File assists organizations by providing support for compliance at all levels. It also identifies controlled substances by National Drug Code (NDC), enabling compatibility with a variety of databases and drug information systems. EMR and CPOE vendors and self-programmers can employ the file to develop rules, applications, and reports based on the needs of their users, aiding in the creation of quality assurance programs around controlled substances.
“Due to concerns over prescription drug abuse, government authorities in the U.S. continue to increase verification, monitoring, and reporting requirements for controlled substances,” said David Del Toro, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “The Medi-Span Controlled Substances File was designed based on customer feedback to help make meeting compliance easier by reducing the time spent manually researching and monitoring the varying federal, state, and territory restrictions on controlled substances.”
Medi-Span is part of , a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of , a market-leading global information services company with annual revenues (2012) of €3.6 billion ($4.6 billion), approximately 19,000 employees worldwide and operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.